Key result
Combining antiplatelets and anticoagulants reduces MACE in patients with coronary artery ectasia.
Why the study?
Does antiplatelet therapy combined with anticoagulants reduce major cardiovascular events in patients with coronary artery ectasia?
Does antiplatelet therapy combined with anticoagulants reduce major cardiovascular events in patients with coronary artery ectasia?
Combining antiplatelet therapy with anticoagulants may offer better protection against major adverse cardiovascular events in patients with coronary artery ectasia.
May support combined antiplatelet-anticoagulant therapy to reduce MACE in coronary artery ectasia; leaves open need for confirmatory RCTs given limited evidence.
It can be concluded that antiplatelet (SAPT/DAPT) must be applied in combination with anticoagulants to provide more efficient protection against MACE in CAE patients. However, further high-quality randomized clinical trials are needed to confirm the results.
No takes yet. Share an insight, caveat, or question.
Amirpour et al. (2024) studied this question. Antiplatelet therapy combined with anticoagulants offers more effective protection against major cardiovascular events in patients with coronary artery ectasia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: